Healthcare Services

Trigeminal Neuralgia Treatment Market Outlook Driven by Growth Factors

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Trigeminal Neuralgia Treatment Market From 2026 To 2030?

The trigeminal neuralgia treatment market size has experienced robust expansion in recent years. It is anticipated to grow from $0.73 billion in 2025 to $0.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. The market’s expansion in the past was driven by factors such as increasing diagnosis rates of trigeminal neuralgia, a continued reliance on pharmacological pain management, the expansion of neurology specialty services, improved imaging for nerve disorders, and the growing availability of surgical treatment options.

The trigeminal neuralgia treatment market is projected to experience robust expansion in the coming years. By 2030, its value is anticipated to reach $1 billion, exhibiting a compound annual growth rate (CAGR) of 6.4%. This expansion during the projection period can be attributed to several factors, including a heightened demand for lasting pain relief solutions, increased adoption of gamma knife radiosurgery, the proliferation of outpatient surgical centers, an amplified emphasis on patient quality-of-life outcomes, and breakthroughs in neurosurgical techniques. Key developments expected during this timeframe involve the greater utilization of advanced anticonvulsant medications, a surge in the embrace of minimally invasive surgical procedures, a burgeoning inclination towards stereotactic radiosurgery, the broadening of multidisciplinary pain management approaches, and a stronger concentration on long-term symptom control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21307&type=smp

Which Major Drivers Are Influencing The Expansion Of The Trigeminal Neuralgia Treatment Market?

The increasing occurrence of neurological disorders is anticipated to drive the expansion of the trigeminal neuralgia treatment market. Neurological disorders encompass various conditions affecting the brain, spinal cord, and nerves. The rising prevalence of these disorders is primarily linked to the aging demographic, as older individuals face a higher risk of developing conditions such as Alzheimer’s, Parkinson’s, and stroke. Trigeminal neuralgia treatments offer support to patients by alleviating severe facial pain, reducing nerve irritation, enhancing their quality of life, and preventing further neurological damage. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, and this number is projected to rise to 13.8 million by 2060. Therefore, the growing incidence of neurological disorders is propelling the growth of the trigeminal neuralgia treatment market. The expanding elderly population is expected to fuel the growth of the trigeminal neuralgia treatment market. The geriatric population consists of individuals typically aged 65 years and older, who often have elevated healthcare needs due to age-related physiological changes, chronic illnesses, and functional limitations. The increase in the geriatric population is a result of extended life expectancy, advancements in healthcare, lower birth rates, improved living standards, better disease management, reduced infant mortality, enhanced nutrition, and access to medical innovations. Trigeminal neuralgia treatment assists the elderly by alleviating intense facial pain, improving daily functioning, and enhancing their overall quality of life. For instance, in October 2024, according to World Health Organization, a Switzerland-based intergovernmental organization, the global population of individuals aged 60 and older is projected to hit 1.4 billion by 2030, making up one in every six people worldwide. This figure is expected to double to 2.1 billion by 2050, with the number of people aged 80 and above set to triple, reaching 426 million. Consequently, the aging population is driving the growth of the trigeminal neuralgia treatment market.

What Are The Different Segment Types In The Trigeminal Neuralgia Treatment Market Segment Breakdown?

The trigeminal neuralgia treatment market covered in this report is segmented –

1) By Treatment Type: Medications, Surgery, Other Treatment Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Medications: Anticonvulsants, Muscle Relaxants, Antidepressants

2) By Surgery: Microvascular Decompression Surgery, Gamma Knife Radiosurgery, Rhizotomy

3) By Other Treatment Types: Nerve Blocks, Stereotactic Radiosurgery, Physical Therapy

Which Trends Are Shaping The Trigeminal Neuralgia Treatment Market?

Major companies in the trigeminal neuralgia treatment market are dedicated to developing innovative solutions, such as minimally invasive nerve ablation, with the aim of improving patient outcomes, reducing complications associated with procedures, and enhancing the overall quality of life for individuals suffering from severe facial pain. Minimally invasive nerve ablation is a medical technique that utilizes heat, cold, or chemical agents to selectively destroy or disable nerves responsible for pain, causing minimal damage to surrounding tissues. For instance, in August 2025, NeuroOne Medical Technologies Corporation, a US-based medical technology company, obtained approval from the U.S. Food and Drug Administration (FDA) for the OneRF Trigeminal Nerve Ablation System, authorizing its use for treating trigeminal neuralgia, a chronic facial pain condition. The system features a multi-contact radiofrequency probe that facilitates precise pain localization, stimulation, and customized ablation using a single electrode. It functions with temperature-controlled lesioning to boost accuracy and safety, potentially decreasing procedure time and elevating patient comfort. The system is minimally invasive and delivers targeted radiofrequency energy to ablate nerve fibers responsible for chronic facial pain, such as trigeminal neuralgia.

Who Are The Well-Known Companies In The Trigeminal Neuralgia Treatment Market?

Major companies operating in the trigeminal neuralgia treatment market are Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Elekta, Accuray Inc., UCB S.A., Eli Lilly and Company

Get The Full Trigeminal Neuralgia Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/trigeminal-neuralgia-treatment-global-market-report

Which Region Dominates The Trigeminal Neuralgia Treatment Market By Market Share?

North America was the largest region in the trigeminal neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trigeminal neuralgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Trigeminal Neuralgia Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/trigeminal-neuralgia-treatment-global-market-report

Browse Through More Reports Similar to the Global Trigeminal Neuralgia Treatment Market 2026, By The Business Research Company

Fibromyalgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Muscle Pain Treatment Market Report

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Migraine Treatment Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795